{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+-+Inhibition&page=16",
    "query": {
      "intervention": "Control - Inhibition",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 372,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+-+Inhibition&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+-+Inhibition&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T02:34:45.958Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04076553",
      "title": "Augmenting Cognitive Behavioral Therapy With Inhibitory Control Training",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Binge-Eating Disorder",
        "Bulimia Nervosa"
      ],
      "interventions": [
        {
          "name": "CBT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ICT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Drexel University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2019-10-15",
      "completion_date": "2022-07",
      "has_results": false,
      "last_update_posted_date": "2021-08-09",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04076553"
    },
    {
      "nct_id": "NCT06029673",
      "title": "Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lactation Suppressed"
      ],
      "interventions": [
        {
          "name": "Cabergoline 1 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 69,
      "start_date": "2024-02-07",
      "completion_date": "2025-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 2,
      "location_summary": "San Jose, California • Stanford, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06029673"
    },
    {
      "nct_id": "NCT04543942",
      "title": "Sex Differences in Risk for Alcohol Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "Alcohol",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Fillmore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "21 Years to 29 Years"
      },
      "enrollment_count": 28,
      "start_date": "2019-11-01",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-09-04",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04543942"
    },
    {
      "nct_id": "NCT05781750",
      "title": "A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "zetomipzomib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kezar Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2023-11-03",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 4,
      "location_summary": "Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more",
      "locations": [
        {
          "city": "Lake Charles",
          "state": "Louisiana"
        },
        {
          "city": "East Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Colleyville",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05781750"
    },
    {
      "nct_id": "NCT05429671",
      "title": "Antibiotic Loaded Cement After TKA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Total Knee Arthoplasty"
      ],
      "interventions": [
        {
          "name": "total knee arthroplasty",
          "type": "PROCEDURE"
        },
        {
          "name": "Tobramycin",
          "type": "DRUG"
        },
        {
          "name": "Gentamicin",
          "type": "DRUG"
        },
        {
          "name": "Antibiotic cement spacer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Rothman Institute Orthopaedics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-06-20",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05429671"
    },
    {
      "nct_id": "NCT00865306",
      "title": "Early Intervention for Children at Risk for Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "\"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents.\"",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "4 Years to 7 Years"
      },
      "enrollment_count": 65,
      "start_date": "1998-03",
      "completion_date": "2005-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865306"
    },
    {
      "nct_id": "NCT02404350",
      "title": "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 997,
      "start_date": "2015-08-31",
      "completion_date": "2019-01-24",
      "has_results": true,
      "last_update_posted_date": "2020-04-20",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 22,
      "location_summary": "Upland, California • Aurora, Colorado • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404350"
    },
    {
      "nct_id": "NCT02983240",
      "title": "Electrical Inhibition of Human Preterm Contractions",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Preterm Labor",
        "PreTerm Birth",
        "Preterm Labor With Delivery Nos"
      ],
      "interventions": [
        {
          "name": "Electrical Uterine Pacemaker",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "e-Bio Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2017-03-01",
      "completion_date": "2026-01-21",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02983240"
    },
    {
      "nct_id": "NCT05152888",
      "title": "The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stable Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05152888"
    },
    {
      "nct_id": "NCT00326339",
      "title": "Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "R788",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 189,
      "start_date": "2006-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-04-20",
      "last_synced_at": "2026-10-22T02:34:45.958Z",
      "location_count": 27,
      "location_summary": "Santa Maria, California • Ocala, Florida • Orange Park, Florida + 22 more",
      "locations": [
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326339"
    }
  ]
}